Novo Nordisk A/S
CSE:NOVO B
Novo Nordisk A/S
CSE:NOVO B
Price:
923.1 DKK
-0.61%
Updated:
May 27, 2024
Novo Nordisk A/S
Total Liabilities & Equity
|
Novo Nordisk A/S
Total Liabilities & Equity Peer Comparison
Comparables:
HLUN A
ALK B
Competitive Total Liabilities & Equity Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Novo Nordisk A/S
CSE:NOVO B
|
Total Liabilities & Equity
kr298.9B
|
CAGR 3-Years
28%
|
CAGR 5-Years
22%
|
CAGR 10-Years
17%
|
|
|
H Lundbeck A/S
CSE:HLUN A
|
Total Liabilities & Equity
kr37.4B
|
CAGR 3-Years
1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ALK-Abello A/S
CSE:ALK B
|
Total Liabilities & Equity
kr6.7B
|
CAGR 3-Years
7%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
See Also
What is Novo Nordisk A/S's Total Liabilities & Equity?
Total Liabilities & Equity
298.9B
DKK
298.9B
DKK
Based on the financial report for Mar 31, 2024, Novo Nordisk A/S's Total Liabilities & Equity amounts to 298.9B DKK.
What is Novo Nordisk A/S's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
17%
17%
Over the last year, the Total Liabilities & Equity growth was 20%. The average annual Total Liabilities & Equity growth rates for Novo Nordisk A/S have been 28% over the past three years , 22% over the past five years , and 17% over the past ten years .
You don't have any saved screeners yet
